Bellevue Group AG Takes $145,000 Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Bellevue Group AG acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 3,300 shares of the company’s stock, valued at approximately $145,000.

Several other large investors have also recently bought and sold shares of the company. Covestor Ltd lifted its stake in shares of IDEAYA Biosciences by 9,225.0% during the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after acquiring an additional 1,107 shares during the period. JTC Employer Solutions Trustee Ltd bought a new position in shares of IDEAYA Biosciences during the 1st quarter valued at about $67,000. AJOVista LLC acquired a new position in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $99,000. SG Americas Securities LLC bought a new stake in shares of IDEAYA Biosciences during the first quarter worth $101,000. Finally, O Shaughnessy Asset Management LLC acquired a new stake in shares of IDEAYA Biosciences during the first quarter worth $214,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

Insider Activity

In other IDEAYA Biosciences news, CEO Yujiro S. Hata sold 34,433 shares of IDEAYA Biosciences stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $41.81, for a total value of $1,439,643.73. Following the completion of the sale, the chief executive officer now owns 677,887 shares in the company, valued at approximately $28,342,455.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Yujiro S. Hata sold 56,711 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total value of $2,359,744.71. Following the completion of the transaction, the chief executive officer now owns 677,887 shares of the company’s stock, valued at $28,206,878.07. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Yujiro S. Hata sold 34,433 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $41.81, for a total transaction of $1,439,643.73. Following the sale, the chief executive officer now owns 677,887 shares in the company, valued at $28,342,455.47. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,644 shares of company stock valued at $4,832,228. 3.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

IDYA has been the subject of a number of research analyst reports. Wedbush reiterated an “outperform” rating and set a $54.00 target price (down previously from $56.00) on shares of IDEAYA Biosciences in a report on Tuesday, July 16th. The Goldman Sachs Group decreased their price target on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating for the company in a research note on Monday, May 13th. BTIG Research boosted their price objective on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 9th. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $65.00 to $69.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Finally, Royal Bank of Canada raised their price objective on IDEAYA Biosciences from $53.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Fourteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $52.92.

IDEAYA Biosciences Stock Performance

IDYA traded down $0.04 during trading hours on Monday, reaching $42.35. The company’s stock had a trading volume of 256,305 shares, compared to its average volume of 918,814. The company’s 50-day moving average is $38.34 and its 200-day moving average is $41.27. IDEAYA Biosciences, Inc. has a 52 week low of $21.22 and a 52 week high of $47.74. The firm has a market cap of $3.21 billion, a PE ratio of -21.09 and a beta of 0.86.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. The business’s revenue was down 100.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.49) EPS. Equities analysts anticipate that IDEAYA Biosciences, Inc. will post -2.22 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.